UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Investigational new drugs, 2020-10, Vol.38 (5), p.1570-1579

2020

Volltextzugriff (PDF)

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Journal of pharmacokinetics and pharmacodynamics, 2010-02, Vol.37 (1), p.3-24

2010

Volltextzugriff (PDF)

Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs

Journal of pharmacokinetics and pharmacodynamics, 2007-06, Vol.34 (3), p.313-331

2007

Volltextzugriff (PDF)

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2015-12, Vol.76 (6), p.1143-1152

2015

Volltextzugriff (PDF)

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

Pharmaceutical research, 2014-10, Vol.31 (10), p.2829-2843

2014

Volltextzugriff (PDF)

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673-680

2017

Volltextzugriff (PDF)

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Journal of pharmacokinetics and pharmacodynamics, 2004-06, Vol.31 (3), p.185-213

2004

Volltextzugriff (PDF)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Investigational new drugs, 2015-04, Vol.33 (2), p.357-370

2015

Volltextzugriff (PDF)

Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

Cancer chemotherapy and pharmacology, 2019-11, Vol.84 (5), p.1003-1015

2019

Volltextzugriff (PDF)

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Cardiovascular toxicology, 2015-10, Vol.15 (4), p.309-323

2015

Volltextzugriff (PDF)

Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling

The AAPS journal, 2015-11, Vol.17 (6), p.1395-1406

2015

Volltextzugriff (PDF)

Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9

Journal of pharmacokinetics and pharmacodynamics, 2012-04, Vol.39 (2), p.147-160

2012

Volltextzugriff (PDF)

A phase 1 study of anti-TGF[beta] receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673

2017

Volltextzugriff (PDF)

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

European journal of clinical pharmacology, 2007-05, Vol.63 (5), p.485-498

2007

Volltextzugriff (PDF)

Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs

Journal of pharmacokinetics and pharmacodynamics, 2006-10, Vol.33 (5), p.571-594

2006

Volltextzugriff (PDF)

Cardiac Safety of TGF-[beta] Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Cardiovascular toxicology, 2015-10, Vol.15 (4), p.309

2015

Volltextzugriff (PDF)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-[beta] receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Investigational new drugs, 2015-04, Vol.33 (2), p.357

2015

Volltextzugriff (PDF)

Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis : diazepam case study

Journal of pharmacokinetics and pharmacodynamics, 2006-02, Vol.33 (1), p.1-27

2006

Volltextzugriff (PDF)

A comment on the "correction" of tissue-plasma partition coefficients for drug extraction in eliminating organs by Sven Björkman

Journal of pharmacokinetics and pharmacodynamics, 2005-12, Vol.32 (5-6), p.659-662

2005

Volltextzugriff (PDF)

Optimal design for multivariate response pharmacokinetic models

Journal of pharmacokinetics and pharmacodynamics, 2006-04, Vol.33 (2), p.97-124

2006

Volltextzugriff (PDF)

Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan

Pharmaceutical research, 2005-10, Vol.22 (10), p.1614-1626

2005

Volltextzugriff (PDF)

Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios

Journal of pharmacokinetics and pharmacodynamics, 2004-08, Vol.31 (4), p.269-298

2004

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling

Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9

A phase 1 study of anti-TGF[beta] receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs

Cardiac Safety of TGF-[beta] Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-[beta] receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis : diazepam case study

A comment on the "correction" of tissue-plasma partition coefficients for drug extraction in eliminating organs by Sven Björkman

Optimal design for multivariate response pharmacokinetic models

Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan

Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios

Aktive Filter

Suchergebnisse filtern